AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first ...

Johnson & Johnson JNJ and AstraZeneca AZN rank among the world’s largest pharmaceutical companies, each with a broad and ...

AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood Cancer by Vandana Singh Benzinga Editor Follow ...

Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall ...

AstraZeneca AZN-Q -1.14% on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, ...

AstraZeneca AZN announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the expanded use of Calquence (acalabrutinib) in mantle cell lymphoma (MCL).

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “ These impactful results in mantle cell lymphoma show that bringing CALQUENCE to the first-line setting significantly ...

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Based on these impressive data from the AMPLIFY trial, CALQUENCE is the only second-generation BTK inhibitor to ...

The newest BTK inhibitor on the market, Eli Lilly’s Jaypirca, has s | In a phase 3 trial, the newest Bruton’s tyrosine kinase ...

WILMINGTON, Del. -- (BUSINESS WIRE)-- AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients ...

FDA fully approves AstraZeneca's Calquence combo therapy, reducing MCL progression/death risk by 27% in Phase 3 ECHO trial. Median progression-free survival extended to 66.4 months with Calquence ...